Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

Fig. 3

WM35 and WM35-R were treated with trametinib or vemurafenib. Growth inhibition curves by SRB assay for WM35 and WM35-R treated with trametinib (a) or vemurafenib (b) for 72 h. Two way ANOVA was used to test the difference between the cell lines for concentrations higher than GI50 (***p < 0.001; ****p < 0.0001). Comparison of GI50 for trametinib (c) and vemurafenib (d) for WM35 and WM35-R. Immunobloting of WM35 and WM35-R following treatment with trametinib (e) or vemurafenib (f) for 6 h

Back to article page